Q-omics provides the consensus-scored ZNF529 profile across patient tissues and cancer cell-line models. ZNF529 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF529 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, ZNF529 RNA expression shows 20,943 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where ZNF529 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF529 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF529 survival associations across molecular data types. ZNF529 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF529 RNA expression–survival associations across cancer types. High ZNF529 expression shows unfavorable associations in LGG and LIHC, but favorable associations in HNSC, UCS, BRCA and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF529 RNA expression.
This table summarizes ZNF529 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF529. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF529 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, CHOL, KIRP and KIRC. The LIHC box plot shows higher ZNF529 RNA expression in tumor versus normal tissue (log2 FC = +0.823, t-test p < 0.001).
This table shows molecular features associated with ZNF529 in patient tissues and cancer cell lines. In patient samples, ZNF529 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF529 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
